Results 61 to 70 of about 3,203 (180)
Effects of paricalcitol on the expression of β-catenin and the vitamin D receptor (VDR).
, 2013 The expression of β-catenin increased in HK-2 cells treated with 10 µM HHE for 6 h. In contrast, the expression of VDR decreased after HHE treatment. Paricalcitol pretreatment significantly attenuated these changes.
Joon Seok Choi (413565) +8 more
core +1 more source
Meta-analysis of the clinical efficacy of paricalcitol in the treatment of chronic kidney disease
Linchuang shenzangbing zazhiObjectiveTo evaluate the overall clinical efficacy of paricalcitol in patients with stage 3 to 5 chronic kidney disease （CKD）.MethodsStudies on the efficacy of paricalcitol in the treatment of patients with CKD， published up to January 2025， were ...
Wang Shi-han, Zang Xiu-juan
doaj
Paricalcitol-loaded PLGA nanodrug for the amelioration of sepsis-associated acute kidney injury
Materials & DesignSepsis-associated acute kidney injury (SA-AKI) is a severe clinical condition with a high mortality. Currently, there is no specific therapy for SA-AKI, and clinicians can only rely on extensive supportive treatment.
Zhi Li +9 more
doaj +1 more source
Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
Kidney International Reports, 2018 Secondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications.
Josep M. Cruzado +13 more
doaj +1 more source
Медицинский совет, 2018 A review of the literature is devoted to the issue of secondary hyperparathyroidism (SHPT) with underlying chronic renal failure. Initial manifestations of the disease can be observed even with a minimal decrease in the rate of glomerular filtration and ...
Zh. E. Belaya, L. Ya. Rozhinskaya
doaj +1 more source
, 2010 <i>Background/Aims:</i> Parathyroidectomies are performed when medical therapy fails to control secondary hyperparathyroidism in hemodialysis patients.
Dennis L. Andress +5 more
core +1 more source
Administered paricalcitol dose and survival in hemodialysis patients: A marginal structural model analysis [PDF]
, 2012 PurposeSeveral observational studies have indicated that vitamin D receptor activators (VDRA), including paricalcitol, are associated with greater survival in maintenance hemodialysis (MHD) patients.
Arah, Onyebuchi A +7 more
core +1 more source
, 2015 The erythropoiesis-stimulating agent (ESA) hyporesponsiveness index (EHRI) calculated as the weekly dose of EPO divided by weight (kg) divided by hemoglobin level (g/dL) has been considered useful to assess ESA resistance.
Baris Afsar +5 more
core +1 more source
Oral paricalcitol as antiproteinuric agent in chronic kidney disease.
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2013 Background: Vitamin D has an important regulatory effect on the renin-angiotensin-aldosterone system, playing a central role in the regulation of proteinuria. We therefore studied the antiproteinuric effect of paricalcitol. Methods: 36 patients with an estimated GFR of 30-90mL/min/1.73m² and proteinuria >400mg/d with a stable dose of ACE inhibitor or ...
Lorenzo, Alberto de +7 more
openaire +4 more sources
Paricalcitol Protects Peritoneal Membrane Function in Encapsulating Peritoneal Sclerosis
Turkish Journal of Nephrology, 2019 OBJECTIVE: The most lethal complication of peritoneal dialysis is encapsulating peritoneal sclerosis (EPS), which develops as a result of epithelio-mesenchymal transformation (EMT) and known fibrotic processes.
Cuma Bülent GÜL +10 more
doaj